Literature DB >> 2685009

Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children.

M Rosenbaum1, J M Gertner, R L Leibel.   

Abstract

Chronic administration of exogenous GH to GH-deficient children is associated with a redistribution of adipose tissue from an abdominal (android) to a more peripheral (gynoid) distribution. We studied abdominal and gluteal sc adipose tissue from seven GH-deficient children 1) before beginning and 2) after 3 months of therapy with exogenous GH (0.1 mg/kg, sc, three times per week). In abdominal and gluteal adipocytes, we measured lipid content and rates of in vitro lipolysis and lipogenesis in response to insulin and various adrenoreceptor agonists. These results were correlated with measures of statural growth and adipose tissue distribution in each subject. We found that GH therapy was associated with a significant reduction in abdominal adipocyte size (0.68 +/- 0.09 micrograms lipid/cell before therapy vs. 0.49 +/- 0.07 after therapy; P less than 0.05), a significant reduction in overall basal rates of lipogenesis (0.43 +/- 0.06 mumol [14C]acylglyceride synthesized/10(6) cells.2 h before therapy vs. 0.27 +/- 0.09 after therapy), and with variable desensitization of abdominal sc adipose tissue to the antilipolytic effect of insulin. The extent of this decrease in insulin action was significantly correlated with changes in abdominal adipocyte lipid content (r = 0.77; P less than 0.05), and with the changes in the anatomical distribution of fat during the study period (r = 0.97; P less than 0.001), as measured by the relative lipid content per adipocyte at each site. We conclude that the site-specific changes in adipose distribution during GH administration are due in part to anatomical site-specific GH-mediated changes in insulin responsiveness of adipose tissue and that exogenous GH therapy is associated with a decrease in de novo triglyceride synthesis in GH-deficient children.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685009     DOI: 10.1210/jcem-69-6-1274

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

2.  Effect of growth hormone on fatty liver in panhypopituitarism.

Authors:  S Takano; S Kanzaki; M Sato; T Kubo; Y Seino
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

3.  Metabolic effects of growth hormone treatment: an early predictor of growth response?

Authors:  J W Gregory; S A Greene; R T Jung; C M Scrimgeour; M J Rennie
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

Review 4.  Renal effects of growth hormone. II. Electrolyte homeostasis and body composition.

Authors:  G D Ogle; A R Rosenberg; G Kainer
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 5.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

Review 6.  Effects of GH and insulin-like growth factor-I on body composition.

Authors:  J Svensson; L Lönn; G Johannsson; B A Bengtsson
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 7.  The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.

Authors:  Moira S Lewitt
Journal:  Biochem Insights       Date:  2017-04-20

8.  Redundancy in regulation of lipid accumulation in skeletal muscle during prolonged fasting in obese men.

Authors:  Morten L Høgild; Anders Gudiksen; Henriette Pilegaard; Hans Stødkilde-Jørgensen; Steen Bønløkke Pedersen; Niels Møller; Jens O L Jørgensen; Niels Jessen
Journal:  Physiol Rep       Date:  2019-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.